[go: up one dir, main page]

MA37501B1 - Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 - Google Patents

Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1

Info

Publication number
MA37501B1
MA37501B1 MA37501A MA37501A MA37501B1 MA 37501 B1 MA37501 B1 MA 37501B1 MA 37501 A MA37501 A MA 37501A MA 37501 A MA37501 A MA 37501A MA 37501 B1 MA37501 B1 MA 37501B1
Authority
MA
Morocco
Prior art keywords
compounds used
pyrazole compounds
sglt1 inhibitors
sglt1
inhibitors
Prior art date
Application number
MA37501A
Other languages
English (en)
Other versions
MA37501A1 (fr
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37501(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA37501A1 publication Critical patent/MA37501A1/fr
Publication of MA37501B1 publication Critical patent/MA37501B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule (ii) : x représentant ce qui suit : ou un sel pharmaceutiquement acceptable de celui-ci.
MA37501A 2012-05-10 2014-11-05 Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 MA37501B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26
PCT/US2013/039164 WO2013169546A1 (fr) 2012-05-10 2013-05-02 Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1

Publications (2)

Publication Number Publication Date
MA37501A1 MA37501A1 (fr) 2016-03-31
MA37501B1 true MA37501B1 (fr) 2016-11-30

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37501A MA37501B1 (fr) 2012-05-10 2014-11-05 Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1

Country Status (43)

Country Link
US (2) US8697849B2 (fr)
EP (1) EP2850084B1 (fr)
JP (1) JP6148725B2 (fr)
KR (1) KR101685779B1 (fr)
AP (1) AP3593A (fr)
AR (1) AR090806A1 (fr)
AU (1) AU2013259946B2 (fr)
BR (1) BR112014026198B1 (fr)
CA (1) CA2869323C (fr)
CL (1) CL2014002845A1 (fr)
CO (1) CO7141429A2 (fr)
CR (1) CR20140473A (fr)
CY (1) CY1117912T1 (fr)
DK (1) DK2850084T3 (fr)
DO (1) DOP2014000250A (fr)
EA (1) EA024207B1 (fr)
EC (1) ECSP14026088A (fr)
ES (1) ES2588835T3 (fr)
GT (1) GT201400242A (fr)
HK (1) HK1202542A1 (fr)
HR (1) HRP20160804T1 (fr)
HU (1) HUE030414T2 (fr)
IL (1) IL235427A (fr)
IN (1) IN2014DN07996A (fr)
JO (1) JO3136B1 (fr)
LT (1) LT2850084T (fr)
MA (1) MA37501B1 (fr)
ME (1) ME02405B (fr)
MX (1) MX357058B (fr)
MY (1) MY177326A (fr)
NZ (1) NZ700356A (fr)
PE (1) PE20142399A1 (fr)
PH (1) PH12014502492B1 (fr)
PL (1) PL2850084T3 (fr)
PT (1) PT2850084T (fr)
RS (1) RS55107B1 (fr)
SG (1) SG11201407345QA (fr)
SI (1) SI2850084T1 (fr)
TN (1) TN2014000410A1 (fr)
TW (1) TWI579295B (fr)
UA (1) UA113086C2 (fr)
WO (1) WO2013169546A1 (fr)
ZA (1) ZA201407531B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
JO3298B1 (ar) 2013-11-01 2018-09-16 Lilly Co Eli مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
TWI805727B (zh) * 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
EP4026564A4 (fr) * 2019-09-04 2023-03-15 Japan Tobacco Inc. Procédé thérapeutique ou prophylactique pour le diabète utilisant la polythérapie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3989730B2 (ja) 1999-08-31 2007-10-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物およびその製造中間体
DE60230591D1 (de) 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
WO2002098893A1 (fr) 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci
JP4540475B2 (ja) * 2002-08-08 2010-09-08 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
BRPI0711949A2 (pt) * 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
EP2228378B1 (fr) 2007-12-27 2015-09-09 Kissei Pharmaceutical Co., Ltd. Monosébacate d'un dérivé de pyrazole
BRPI1008653A2 (pt) 2009-02-23 2016-03-08 Taisho Pharmaceutical Co Ltd compostos 4-isopropil fenil glicitol como inibidores de sglt1
EP2482823A2 (fr) 2009-10-02 2012-08-08 Sanofi Utilisation de composés à activité inhibitrice de SGLT-1/SGLT-2 pour la production de médicament pour le traitement de maladies osseuses
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
BR112014026198A2 (pt) 2017-06-27
CR20140473A (es) 2014-11-21
SI2850084T1 (sl) 2016-07-29
CY1117912T1 (el) 2017-05-17
EA201491852A1 (ru) 2015-02-27
HRP20160804T1 (hr) 2016-08-12
EP2850084B1 (fr) 2016-06-15
EP2850084A1 (fr) 2015-03-25
WO2013169546A1 (fr) 2013-11-14
CN104284894A (zh) 2015-01-14
JP2015516419A (ja) 2015-06-11
JP6148725B2 (ja) 2017-06-14
PT2850084T (pt) 2016-08-02
PH12014502492A1 (en) 2015-01-12
MX357058B (es) 2018-06-25
CO7141429A2 (es) 2014-12-12
MA37501A1 (fr) 2016-03-31
AP2014008044A0 (en) 2014-11-30
US20140162967A1 (en) 2014-06-12
DOP2014000250A (es) 2014-11-30
KR20150001798A (ko) 2015-01-06
AU2013259946A1 (en) 2014-10-16
US8697849B2 (en) 2014-04-15
HK1202542A1 (zh) 2015-10-02
JO3136B1 (ar) 2017-09-20
PH12014502492B1 (en) 2015-01-12
CL2014002845A1 (es) 2015-01-30
US9296775B2 (en) 2016-03-29
PE20142399A1 (es) 2015-01-22
MY177326A (en) 2020-09-11
AP3593A (en) 2016-02-15
US20130303471A1 (en) 2013-11-14
GT201400242A (es) 2015-08-27
BR112014026198B1 (pt) 2021-02-02
AU2013259946B2 (en) 2015-09-10
CA2869323A1 (fr) 2013-11-14
IN2014DN07996A (fr) 2015-05-01
AR090806A1 (es) 2014-12-10
ECSP14026088A (es) 2015-09-30
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
SG11201407345QA (en) 2014-12-30
TN2014000410A1 (en) 2015-12-21
IL235427A (en) 2016-06-30
CA2869323C (fr) 2016-03-29
RS55107B1 (sr) 2016-12-30
PL2850084T3 (pl) 2017-05-31
DK2850084T3 (en) 2016-09-12
ME02405B (fr) 2016-09-20
EA024207B1 (ru) 2016-08-31
TWI579295B (zh) 2017-04-21
LT2850084T (lt) 2016-09-12
ES2588835T3 (es) 2016-11-07
CN104284894B (zh) 2016-02-17
ZA201407531B (en) 2016-05-25
TW201406773A (zh) 2014-02-16
HUE030414T2 (en) 2017-05-29
NZ700356A (en) 2016-06-24
MX2014013615A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA38472A1 (fr) Composé peptidique
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52948B1 (fr) Composés
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
MX350892B (es) Síntesis de compuesto antiviral.
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA40302A1 (fr) Dérivés de carbazole
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MA39983A (fr) Dérivés de carboxamide
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA39305A3 (fr) Dérivés d'éthynyle
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA20150280A2 (fr) Dérivés d'aryléthynyle
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain